News Sentiment

GRCE sentiment intelligence

Grace Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 38 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.38 Week of 19 Jun 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 31

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+8.2% over one week, +8.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 8.2% Price confirming higher
Trend fit Trend inactive 8.2% over four weeks
Fair value -25.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 30
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 31
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 7
simplywall.st 3
Simply Wall Street 2
GuruFocus 1
TradingKey 1
Moomoo 1
The Globe and Mail 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 11
Balance sheet 3
Deals and strategy 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-38 of 38
Simply Wall Street Direct company coverage

Grace Therapeutics (NasdaqCM:GRCE) Stock Price

This article provides a company overview and financial data for Grace Therapeutics (NasdaqCM:GRCE). It highlights the company's market capitalization, recent stock performance, and key financial details such as zero revenue and a reported earnings loss of $6.0 million. The compan

Tone
Neutral 50/100
Event
Earnings
Published
28 Jul 2025 00:39
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Grace Therapeutics And 2 Other US Penny Stocks Worth Watching

This article highlights three US penny stocks—Grace Therapeutics, X4 Pharmaceuticals, and Koil Energy Solutions—that investors might find interesting due to their potential for significant returns, despite the inherent risks. It details their financial health, operational overvie

Tone
Positive 60/100
Event
Market update
Published
20 Dec 2024 00:00
Source
Simply Wall Street
Market source Direct company coverage

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Acasti Pharma Inc. announced its corporate name change to Grace Therapeutics, Inc., effective October 28, 2024, with its trading symbol on Nasdaq changing to "GRCE." This rebranding reflects the company's focus on scientific innovation dating back to the pre-merger Grace Therapeu

Tone
Positive 72/100
Event
Deals and strategy
Published
25 Oct 2024 12:00
Source
Market source
Investing.com Canada Direct company coverage

Acasti Pharma transitions to Grace Therapeutics, trading as GRCE By Investing.com

Acasti Pharma is rebranding to Grace Therapeutics, Inc. and will trade on Nasdaq under the ticker GRCE starting October 28, 2024. The change reflects a return to the company's original identity and its focus on scientific innovation, particularly for its lead drug candidate GTx-1

Tone
Positive 73/100
Event
Market update
Published
25 Oct 2024 09:02
Source
Investing.com Canada
Investing.com Direct company coverage

Acasti Pharma transitions to Grace Therapeutics, trading as GRCE

Acasti Pharma is rebranding to Grace Therapeutics, Inc. and will trade under the new ticker symbol GRCE on Nasdaq starting October 28, 2024. This change marks a return to the company's original identity from before its 2021 merger with Acasti, signaling a renewed focus on its lea

Tone
Positive 72/100
Event
Deals and strategy
Published
25 Oct 2024 09:01
Source
Investing.com